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Background: Management of established severe OHSS requires prolonged hospitalization, occasionally in intensive
care units, accompanied by multiple ascites punctures, correction of intravascular fluid volume and electrolyte
imbalance. The aim of the present study was to evaluate whether it is feasible to manage women with severe
OHSS as outpatients by treating them with GnRH antagonists in the luteal phase.
Methods: This is a single-centre, prospective, observational, cohort study. Forty patients diagnosed with severe
OHSS, five days post oocyte retrieval, were managed as outpatients after administration of GnRH antagonist
(0.25 mg) daily from days 5 to 8 post oocyte retrieval, combined with cryopreservation of all embryos. The primary
outcome measure was the proportion of patients with severe OHSS, in whom outpatient management was not
feasible.
Results: 11.3% (95% CI 8.3%-15.0%) of patients (40/353) developed severe early OHSS. None of the 40 patients
required hospitalization following luteal antagonist administration and embryo cryopreservation. Ovarian volume,
ascites, hematocrit, WBC, serum oestradiol and progesterone decreased significantly (P < 0.001) by the end of the
monitoring period, indicating rapid resolution of severe OHSS.
Conclusions: The current study suggests, for the first time, that successful outpatient management of severe OHSS
with antagonist treatment in the luteal phase is feasible and is associated with rapid regression of the syndrome,
challenging the dogma of inpatient management. The proposed management is a flexible approach that minimizes
unnecessary embryo transfer cancellations in the majority (88.7%) of high risk for OHSS patients.
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Ovarian hyperstimulation syndrome (OHSS) is a serious
complication of ovarian stimulation in patients undergo-
ing in-vitro fertilization (IVF) treatment, which is trig-
gered by human chorionic gonadotrophin (hCG). There
are two main clinical forms of OHSS, early and late
OHSS, depending on the time of onset. Early OHSS is
induced by exogenous hCG administered for final oocyte
maturation, usually occurring within 3–7 days post hCG* Correspondence: stratis.kolibianakis@gmail.com
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reproduction in any medium, provided the or[1,2]. Late OHSS is pregnancy-induced, occurs 12–17 days
post hCG and is triggered by the endogenous hCG pro-
duced by an implanting blastocyst [1,2]. OHSS is further
distinguished in mild, moderate and severe forms, de-
pending on the severity of symptoms [3]. Mild OHSS
lacks clinical significance, moderate OHSS requires care-
ful patient monitoring, while severe OHSS may prove to
be critical or even life-threatening, characterized by mas-
sive ovarian enlargement, ascites, pleural effusion, oliguria,
haemoconcentration, adult respiratory distress syndrome
and thromboembolic phenomena, and may require hos-
pitalization in an intensive care unit [4,5].
Severe OHSS, although infrequent in the general IVF
population, represents a really difficult situation for bothtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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published incidence of severe OHSS after ovarian stimu-
lation for IVF ranges from 10% to 38% [7-9]. This high
variation in the occurrence of OHSS is mainly due to
the lack of a universally accepted criteria for diagnosis
and classification of OHSS [3,10].
It has been reported that in high-risk for OHSS PCOS
patients, the use of GnRH antagonists is associated with
a significantly decreased incidence of OHSS by 20%
compared to the use of the long GnRH agonist protocol
[11]. This observation was confirmed by a recent
Cochrane Review [12], which reported a significant re-
duction in severe OHSS using the GnRH antagonist
protocol in both PCOS patients and the general IVF
population. However, the use of GnRH antagonists may
only decrease the incidence of OHSS, which can still
occur. According to the concept of an OHSS-free clinic
[13], it has been proposed to trigger final oocyte matur-
ation by replacing hCG with GnRH agonist in antagonist
protocols, which appears to totally prevent the syndrome
[14]. However, following GnRH agonist triggering,
embryo transfer in the same cycle is associated with a
significantly lower probability of pregnancy and there-
fore, embryo cryopreservation and transfer in a subse-
quent frozen-thawed cycle is usually performed [14,15].
Despite the availability of agonist triggering in antagonist
protocols, some patients at high risk for OHSS will still
choose to proceed to oocyte retrieval and embryo trans-
fer using a lower dose of hCG to trigger final oocyte
maturation [16] and a proportion of them will eventually
develop OHSS.
It should be emphasized that in patients downregu-
lated with GnRH agonists, which currently represent the
majority of IVF patients, hCG is the only way available
for triggering final oocyte maturation and thus OHSS is
more likely to occur.
Alternatively, the dopamine agonist cabergoline [17],
and more recently quinagolide [18], have been shown to
reduce the incidence and severity of OHSS [17-21].
Currently, despite an extensive list of available preven-
tion methods [6], if severe OHSS occurs there is no
established way of management apart from conservative
treatment, involving correction of fluid and electrolyte
imbalance, prevention of thromboembolism, aspiration
of the ascitic fluid etc. [5].
Recently, it has been suggested that GnRH antagonist
administration in the luteal phase in patients with estab-
lished severe early OHSS appears to prevent patient
hospitalization and to result in quick regression of the
syndrome on an outpatient basis. This intervention
appears to be effective in both agonist and antagonist-
treated patients. However, the existing published data
are three small case series [22-24], which although
promising, require further evaluation.The aim of the present study was to evaluate in a lar-
ger series of patients whether it is feasible to manage
women with established severe early OHSS as outpati-
ents by treating them with GnRH antagonists in the lu-
teal phase and cryopreserving all their embryos.
Methods
Study setting and patient population
This is a prospective observational, cohort study of IVF
patients at high risk for OHSS, performed between Janu-
ary 2007 and December 2010 at Eugonia private Assisted
Reproduction Unit. High risk for OHSS was defined as
the presence of at least 20 follicles ≥11 mm on the day
of triggering of final oocyte maturation [25].
During the study period (2007–2010) 2268 cycles were
performed. Clinical and ongoing pregnancy rates were
57.2% and 49.4% respectively for patients <35 years old,
48.6% and 37.9% respectively for patients 35–39 years
old, and 21.9% and 13.3% respectively for patients
>40 years old. Overall severe early OHSS incidence was
1.76% (95% CI 1.28%-2.37%) (40/2268) and late OHSS
incidence was 0.18% (95% CI 0.06%-0.43%) (4/2268).
Patient management
Patients were fully explained on the last day of stimula-
tion the possible risks in case severe OHSS developed
and were presented with the following options: (a) to
withhold hCG and cancel the cycle, b) to use GnRH
agonist instead of hCG for triggering final oocyte matur-
ation [14] combined with cryopreservation of all
embryos , in case GnRH antagonists had been used to
suppress premature LH surge, and (c) to proceed at least
to oocyte retrieval using 5000 IU hCG for triggering
final oocyte maturation [16] and potentially to embryo
transfer, if OHSS did not occur. In the latter case, if se-
vere OHSS occurred, embryo cryopreservation was per-
formed and patients were treated with GnRH
antagonists in the luteal phase, if possible in an out-
patient setting.
All patients were monitored on days 3 and day 5 post
oocyte retrieval for development of severe OHSS. In
patients who did not develop severe OHSS, embryo
transfer was performed either on day 3 or day 5 post oo-
cyte retrieval according to the number and the quality of
the embryos available.
The study was approved by the institutional ethics re-
view board of Eugonia Assisted Reproduction Unit. A
signed informed consent was obtained from all patients
included in this study.
Criteria for diagnosis of severe OHSS
Diagnosis of severe OHSS at our Unit is a modification
based on previously published classification systems
[4,6,11,17,26-29]. Severe early OHSS was diagnosed in
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least two of the following criteria: large ovaries
(>100 mm maximum diameter) [11,23], haematocrit
(Ht) >45%, white blood cell count (WBC) >15,000/mm3,
hydrothorax, dyspnea, oliguria or abnormal liver func-
tion tests. Our classification criteria for OHSS include
numerical parameters, useful for accurate comparisons.
The existence of ascites was observed when the patient
was in anti (reverse) trendelenburg position.
The classification of ascites used in our Unit (Table 1) is
similar to previously published criteria [6,29] and distin-
guishes different levels of ascites, depending on the accu-
mulation of ascetic fluid. This classification system is
reproducible and more clear compared to the subjective
description “clinical or ultrasound evidence of ascites”
mentioned in previous OHSS classifications [4,26-28,30].
Description of the intervention performed
In patients with established early severe OHSS on day 5
post oocyte retrieval, blastocyst cryopreservation was
performed on the same day, and 0.25 mg of the GnRH
antagonist ganirelix (Orgalutran, Organon, The Nether-
lands) was administered daily, from day 5 until and in-
cluding day 8 post oocyte retrieval, as previously
described [22-24].
None of the 362 patients, including the 40 patients
diagnosed with severe early OHSS, received cortisone
administration [31], fluid paracentesis or coasting.
In addition, in these patients daily 4500 anti-Xa IU
(0.45 ml) tinzaparin sodium (Innohep; LEO Pharmacu-
tica Products Hellas Ltd, Greece) were administered for
thromboprophylaxis, from day 5 post oocyte retrieval
until resolution of the syndrome.
Follow up of OHSS
The follow-up of patients with severe OHSS following
GnRH antagonist administration in the luteal phase
included evaluation of hematocrit, white blood cell
count (WBC) and ultrasound assessment of ovarian size
and ascitic fluid on days 7, 9 and 11 post oocyte re-
trieval. Oestradiol and progesterone concentrations wereTable 1 Classification of ascites used in our Unit
Grade Description
No ascites No presence of flui
Low Small amount of flu
Moderate Increased amount o
Marked Large amount of flu
Massive Significant accumu
Tense Significant accumu
The classification of ascites used in our Unit is similar to previously published criter
accumulation of ascetic fluid when the patient was at the anti-trendelenburg positi
subjective description “clinical or ultrasound evidence of ascites” mentioned in prevmonitored during the same period. Ovarian volume was
calculated using the prolate ellipsoid formula V=
D1xD2xD3x0.523, where D1, D2 and D3 are the three
maximal longitudinal, antero-posterior and transverse
diameters respectively.
Patients who did not develop severe OHSS and pro-
ceeded to embryo transfer were examined again 15 and
30 days after oocyte retrieval for the presence of late
pregnancy-induced OHSS.
Ovarian stimulation
Patients underwent ovarian stimulation for IVF/ICSI
using either a long GnRH agonist downregulation or a
flexible GnRH antagonist protocol (Lainas et al. 2010).
All patients received oral contraceptive pill (OCP) start-
ing on day 2 of spontaneous menses of the cycle prior to
the treatment cycle, after blood test confirmed the pres-
ence of a baseline hormone profile. The OCP contained
0.03 mg ethinyl estradiol (E2) and 0.05 mg gestodene
(Trigynera, Bayer Hellas, Greece). OCPs were taken
daily for 21 days.
In the long GnRH agonist downregulation protocol,
patients were administered s.c. GnRH agonist 0.1 mg
triptorelin (Arvekap, Ipsen, France) daily. The agonist
was started 3 days before discontinuation of the oral
contraceptive. All patients had blood loss after discon-
tinuation of the OCP. When desensitization was
achieved (approximately 10–15 days after the initiation
of GnRH agonists), as evidenced by plasma E2 levels of
≤50 pg/ml, the absence of ovarian follicles and endomet-
rial thickness≤ 6 mm) on transvaginal ultrasound exam-
ination, daily s.c. injection of recombinant FSH (rFSH;
Puregon, Organon, The Netherlands or Gonal-F, Merck-
Serono, Switzerland) was commenced. The dose of
GnRH agonist was decreased on that day to 0.05 mg/day
and continued until and including the day of triggering
of final oocyte maturation.
In the flexible GnRH antagonist protocol patients
started daily recombinant FSH (rFSH) treatment with s.c
injections of follitropin b (Puregon, Organon, The Nether-
lands, or Gonal-F, Merck-Serono, Switzerland), on day 2d
id, barely detectable by ultrasound in the pouch of Douglas
f fluid located in the small pelvis
id reaching the level of the umbilicus
lation of fluid reaching Morrison’s pouch
lation of fluid up to the level of the diaphragm with/without hydrothorax
ia [6,29] and distinguishes different levels of ascites, depending on the
on. This classification system is reproducible and more clear compared to the
ious OHSS classifications [4,26-28,30].
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OCP. All patients had blood loss after discontinuation of
the OCP. Daily s.c administration of 0.25 mg ganirelix
(Orgalutran, Organon, The Netherlands) or 0.25 mg
cetrorelix (Merck-Serono, Switzerland) was initiated when
at least one of the following criteria were fulfilled: (i) the
presence of at least one follicle measuring >14 mm; (ii)
serum E2 levels >600 pg/ml; and (iii) serum LH levels
>10 IU/l. Treatment with rFSH and GnRH antagonist
continued daily thereafter, until and including the day of
triggering of final oocyte maturation.
The starting dose of rFSH was 150 IU/day for all
patients. This dose was adjusted after Day 5 of stimula-
tion, depending on the ovarian response, as assessed by
E2 levels and ultrasound.
Triggering of final oocyte maturation and in vitro
fertilization
Final oocyte maturation was triggered when at least three
follicles of diameter ≥17 mm were present. In patients
who chose to proceed to oocyte retrieval and potentially
embryo transfer, 5000 IU hCG (Pregnyl; Organon, The
Netherlands) were administrated i.m. In patients who
chose to trigger final oocyte maturation with GnRH ago-
nists 0.2 mg of triptorelin (Arvekap, Ipsen, France) was
injected i.m. Transvaginal ultrasound-guided oocyte re-
trieval was performed 36 h later by double lumen needle
aspiration. ICSI was performed only in cases with severe
male factor or previous fertilization failure. Embryos were
cultured in sequential media (Medicult/Origio, Denmark)
for up to five days.
Ultrasound and laboratory assays
All ultrasound measurements were performed using a 7.5
or 6 or 5 MHz vaginal probe (Sonoline Adara, Siemens).
FSH, LH, E2 and P levels were measured using an Immu-
lite analyser and commercially available kits (DPC, Los
Angeles, CA). Analytical sensitivity were 0.1 mIU/ml for
FSH, 0.1 mIU/ml for LH, 15 pg/ml for E2 and 0.2 ng/ml
for P. Intra- and inter-assay precision at the concentra-
tions of most relevance to the current study (expressed as
coefficients of variation) were 2.6 and 5.8% for FSH, 5.9
and 8.1% for LH, 6.3 and 6.4% for E2 and 7.9 and 10% for
progesterone. Hematocrit and white blood cell count were
determined by flow cytometry using Coulter AC.T diff™
Analyzer (Coulter Corporation, Miami, Florida). Coeffi-
cient of variation, specifying imprecision limits for white
(WBC) and red blood cell count (RBC), was 3%.
Hematocrit was computed from the relative volume of
erythrocytes (MCV) [Ht(%)=RBCxMCV/10].
Outcome measures
The primary outcome measure was the proportion of
patients with severe early OHSS, in whom outpatientmanagement was not feasible. Reasons for failure of out-
patient management included: development of throm-
bosis, dyspnoea or tachypnea, severe abdominal pain or
peritoneal signs, intractable nausea and vomiting that
prevented ingestion of food or adequate fluids, severe
oliguria or anuria, tense ascites, hypotension (relative to
baseline), abnormal liver function tests, electrolyte
imbalances, dizziness, or syncope [32]. Patients were
instructed to contact the doctors immediately in case
they fell unwell during the monitoring period for imme-
diate admission to hospital.
Secondary outcome measures included evaluation of
changes in ovarian volume, ascites volume, hematocrit
values and white blood cell count, which reflect progress
or regression of severe OHSS. Moreover, serum
oestradiol and progesterone levels were assessed follow-
ing GnRH antagonist administration in the luteal phase.Statistical analysis
The secondary outcome measures were subjected to
repeated measures ANOVA followed by post-hoc pair-
wise comparisons with Bonferroni correction. The fre-
quency distributions of the ascites levels were subjected
to the chi-square test. The level of significance was set
at 0.05.
Since it was impossible to know in advance the num-
ber of high risk women from the initial cohort who
would develop OHSS and receive the intervention, a
post-hoc power analysis was conducted. In this case,
analysis involved determining the power of the patient
number who received the intervention (n = 40) in the
significant reduction of all the measured parameters
(ovarian volume, hematocrit, WBC, estradiol, progester-
one) from day 5 to day 7. It was found that in all cases
the observed power of the analysis was higher that 90%,
provided that a power of 80% is considered satisfactory.Results
From the cohort of 362 high risk patients included in
the present study, triggering of final oocyte maturation
was performed by administration of 5000 IU of hCG in
353 patients, or by administration of GnRH agonist in 9
patients (Figure 1).
Baseline characteristics of the 353 patients in whom
hCG was injected for triggering final oocyte maturation
and either developed (n = 40) or did not develop
(n = 313) severe early OHSS are shown in Table 2, while
ovarian stimulation and embryological data are shown in
Table 3.
Patients who developed severe early OHSS had similar
baseline characteristics compared to patients who did
not develop severe early OHSS, apart from a signifi-
cantly lower baseline FSH (p = 0.008) (Table 2).
Figure 1 (See legend on next page.)
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Figure 1 Flow chart describing the management approach for patients at high risk for developing OHSS. 10 patients did not develop
severe OHSS and had embryo transfer cancellation due to the following reasons: failed fertilization n= 1, oocyte cryopreservation n= 2, no
blastocyst formation n= 2, embryo cryopreservation due to Rokitansky syndrome n= 1, due to poor endometrium n= 1, absence of sperm on
day of oocyte retrieval and use of donor sperm n= 3. Four patients with positive hCG following ET developed pregnancy-induced late OHSS and
were admitted to the hospital (1.1%, 95% CI: 0.5 to 3.3).
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patients who developed severe early OHSS had lower
total FSH dose (p = 0.014), higher number of follicles
(p < 0.001) and higher oestradiol levels (p < 0.001) on the
day of triggering final oocyte maturation, higher number
of oocytes retrieved (p < 0.001), higher number of mature
oocytes (p < 0.001), and higher number of fertilized
oocytes (p < 0.001) compared to patients who did not de-
velop severe early OHSS (Table 3).
The proportion of patients at high risk for OHSS who
developed severe early OHSS was 11.3% (95% CI 8.3%-
15.0%) (40/353). Incidence of late OHSS in patients at
high risk who were triggered with hCG, did not develop
early OHSS and proceeded to embryo transfer was 1.1%
(95% CI 0.36%-2.71%) (4/353) and was associated with
pregnancy achievement.
All 40 patients with severe early OHSS had blastocyst
cryopreservation in combination with GnRH antagonist
administration.
In all 40 patients with severe early OHSS outpatient
management was feasible and none required
hospitalization following administration of GnRH antag-
onist 5 days after oocyte retrieval and embryo cryo-
preservation (0%, 95% CI: 0 to 8.8). Patient monitoring
showed improvement of patients’ symptoms, ultrasound
and laboratory findings (Figures 2, 3).
In the 40 patients with severe early OHSS diagnosed on
day 5 post oocyte retrieval, the highest values of hematocrit,Table 2 Baseline characteristics for the high risk patients who
did not develop severe OHSS (n =313)
N=313 patients without seve
Age (years) 32.6 ± 4.4
BMI (kg/m2) 23.8 ± 4.8
Duration of infertility (years) 3.8 ± 3.8
Number of previous IVF attempts 1.1 ± 1.8
Baseline FSH (IU/l) 6.7 ± 1.6
Baseline LH(IU/l) 5.4 ± 2.5
Baseline oestradiol (pg/ml) 32.9 ± 14.5
Baseline progesterone (ng/ml) 0.51 ± 0.28
Baseline TSH (mIU/ml) 1.7 ± 0.99
Baseline prolactin (ng/ml) 16.7 ± 11.3
Values are expressed as mean± standard deviation (SD) unless otherwise stated. P-vWBC count, ovarian volume, as well as oestradiol and pro-
gesterone were observed on the day of severe OHSS diag-
nosis (day 5 post oocyte retrieval) (Figure 2).
Compared to Day 5 post oocyte retrieval, hematocrit,
ovarian volume, oestradiol and progesterone declined
significantly (p < 0.01) two days (Day 7) after initiation of
GnRH antagonist administration, while WBC count dis-
played a significant decrease on day 9, compared to day
5 (day of GnRH antagonist initiation) (Figure 2).
All 40 patients with severe OHSS were diagnosed with
significant ascites on the day of GnRH antagonist initiation
(27.5% massive/tense ascites; 72.5% moderate/marked asci-
tes), which progressively declined to moderate levels (35%)
or low/no detectable levels (65%) at the end of the monitor-
ing period (p <0.01) (Figure 3). Three patients (3/303) dis-
played marked ascites on day 11 of monitoring.
One patient with severe early OHSS developed mild
respiratory problems on Day 5 post oocyte retrieval. The
patient was examined by a pathologist, O2 saturation
was checked, and it was decided that admission to hos-
pital was not necessary at that moment. The patient was
instructed to contact the doctors in case she developed
dyspnoea, dizziness, fainting, or general discomfort, for
immediate admission to hospital. However, the mild re-
spiratory problem disappeared within 24 hours, along
with a general improvement of clinical symptoms.
In high risk patients who did not develop severe early
OHSS and proceeded to embryo transfer (n = 303),injected hCG (n= 353) and either developed (n= 40) or
re OHSS N=40 patients with severe OHSS p
32.7 ± 4.0 0.960
24.8 ± 5.2 0.896
10.6 ± 1.4 0.958
1.18 ± 1.93 0.084
5.3 ± 1.4 0.008
5.6 ± 2.2 0.229
51.8 ± 27.0 0.652
0.45 ± 0.23 0.157
1.71 ± 0.92 0.763
16.2 ± 10.5 0.566
alues in bold depict statistical significance (p < 0.05).
Table 3 Ovarian stimulation and embryological data for the high risk patients who injected hCG (n = 353) and either
developed (n = 40) or did not develop severe OHSS (n =313)
N=313 patients without severe OHSS N=40 patients with severe OHSS p
Long protocol (n) 111 16
Antagonist protocol (n) 202 24
Duration of stimulation (days) 10.9± 1.5 10.6± 1.4 0.220
Total FSH (IU) 1909± 636 1890± 740 0.014
Number of follicles on day of hCG 29.0± 4.4 33.8± 7.0 <0.001
Oestradiol on day of hCG (pg/ml) 2956± 1289 3687± 1450 <0.001
Progesterone on day of hCG (ng/ml) 0.99± 0.44 1.1± 0.46 0.183
Number of oocytes retrieved 24.1± 6.1 32.0± 11.0 <0.001
Mature oocytes (in ICSI patients) 14.8± 6.6 20.7± 12.7 <0.001
Type of fertilization (IVF/ICSI/ IVF + ICSI) 72/160 /81 13/15/12 0.236
Number of 2PN 13.5± 10.3 18.4± 9.1 <0.001
Number of embryo transfers performed 303
Day of embryo transfer (Day3/Day5) 131/172
Number of embryos transferred 2.7± 0.6
Values are expressed as mean± standard deviation (SD) unless otherwise stated. P-values in bold depict statistical significance (p < 0.05).
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70.3% (n = 213), 59.1% (n = 179) and 50.5% (n = 153), re-
spectively (Table 4).
Discussion
This is the first observational cohort study in the litera-
ture describing outpatient management of established
severe early OHSS, using administration of GnRH antag-
onist in the luteal phase and cryopreservation of all
embryos. None of the patients evaluated required
hospitalization, suggesting that outpatient management
is feasible using this approach. Luteal antagonist admin-
istration was associated with rapid regression of estab-
lished severe early OHSS, improvement of patient
symptoms and ultrasound and laboratory findings. This
flexible approach allows high risk patients to safely
proceed at least to oocyte retrieval using low dose hCG
for triggering final oocyte maturation, and potentially to
embryo transfer if severe OHSS does not occur, thus
avoiding an unnecessary embryo transfer cancellation in
the majority (88.7%) of high risk patients.
Administration of GnRH antagonist in the luteal phase
appears to result in rapid resolution of severe OHSS as
early as two days after initiation of GnRH antagonist,
with a significant decline of ovarian volume, hematocrit
and ascites, as well as oestradiol and progesterone con-
centrations, confirming previous reports published in
three small case series [22-24]. This rapid decline con-
tinued in a progressive manner until the end of the
monitoring period.
The rapid decrease of ovarian volume, oestradiol and
progesterone levels, observed in the patients with estab-
lished severe OHSS, suggests a luteolytic effect of theGnRH antagonist, as recently proposed [23,24]. It is
believed that hCG administration for triggering of final
oocyte maturation induces massive luteinization, ele-
vated secretion of angiogenic factors (such as vascular
endothelial growth factor, angiotensin II, interleukins,
histamine, prolactin, prostaglandins, endothelin-1, selec-
tins) from multiple corpora lutea of hyperstimulated
ovaries, leading to an increase of vascular permeability,
fluid shift to the third space and finally development of
OHSS [33-36].The luteolysis induced by GnRH antagon-
ist possibly leads to a decrease of ovarian activity and to
minimized secretion of locally produced angiogenic fac-
tors, resulting in regression of severe OHSS.
The results obtained in the current study might be
explained by a direct action of GnRH antagonist on the
ovary. The presence and function of extrapituitary
GnRH receptors has been demonstrated in several tis-
sues, including the human ovary [37]. In addition
GnRH antagonists have been shown to inhibit the ex-
pression of locally produced ovarian angiogenic factors,
such as VEGF [38], in human granulosa luteal cell
cultures.
It seems unlikely that the luteolytic action of GnRH
antagonist occurs by a decrease in LH secretion, since
LH concentrations following ovarian stimulation for IVF
are deeply suppressed in the luteal phase [39].
It can be assumed that severe OHSS resolution
observed within the monitoring period of the current
study may be due to the action of GnRH antagonist ra-
ther than natural course of the syndrome. It is recog-
nized that OHSS is a self-limited disease, which however
requires an extensive period for natural regression, with
prolonged hospitalization ranging from 11 to 23 days
Figure 2 Concentrations of (a) oestradiol (b) progesterone, (c) left and (d) right ovarian volume, (e) hematocrit, and (f) white blood
cells during the monitoring period. Asterisks depict statistically significant difference compared to day 5 (*P < 0.001). Oocyte retrieval was
performed on day 0. GnRH antagonist was administered from day 5 until and including day 8 post oocyte retrieval, as indicated by arrows.
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by multiple ascites punctures, human albumin adminis-
tration, correction of intravascular fluid volume and
electrolyte imbalance [32]. On the contrary, our pro-
posed approach resulted in rapid regression of severe
OHSS as early as two days after initiation of GnRH an-
tagonist, without any use of invasive treatment for the
patients and avoiding the need for hospitalization.It has been shown that while elective embryo cryo-
preservation can prevent pregnancy-induced late OHSS,
it cannot completely eliminate early OHSS, which is
induced by exogenous administration of hCG for trig-
gering final oocyte maturation [3,41-43].
In addition, it was recently proposed that early OHSS can
be equally severe as late OHSS, requiring a mean of 6.8 to
20 days of hospitalization depending on whether the
Figure 3 Distribution of ascites levels during the monitoring period. *At the end of the monitoring period, on day 11, “moderate-marked
ascites” included 14 women (35%), of which 11 (27.5%) had moderate ascites, and only 3 (7.5%) had marked ascites. No women (0%) had
“massive-tense” ascites, while the majority of women (65%) had no or low levels of ascites on day 11 of monitoring (chi-square p< 0.01).
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previous reports showing that late pregnancy-induced
OHSS is associated with more severe symptoms [1,2].
In the present study, only 11.3% (95% CI 8.3%-15.0%)
(40/353) of high risk patients receiving hCG developed
severe OHSS and required the intervention (i.e. GnRH
antagonist administration and cryopreservation of all
embryos). The occurrence of severe OHSS presented
here is in agreement with the 12.6% rate shown for PCO
patients [9], and is at the lower end (10%) of the inci-
dence range previously reported in the literature for high
risk patients (10-38%) [7,8]. In addition, the extremely
low percentage (1.1%) of late OHSS in the present study
is significantly lower than the 10% rate of late OHSS
previously reported for women with polycystic ovaries
[2], probably indicating the importance of accurate iden-
tification and monitoring of high risk patients. Using the
proposed approach, it is possible to minimize the occur-
rence of late OHSS by accurate diagnosis of early severe
OHSS prior to the performance of embryo transfer.
Despite the prevention of late OHSS by elective
embryo cryopreservation shown in the present study,
the possible transfer of embryos combined with luteal
administration of GnRH antagonist could potentially be
problematic and lead to lower implantation rates due toTable 4 Pregnancy rates in high risk patients who did not
develop severe early OHSS and proceeded to embryo
transfer (n = 303)
Pregnancy type Rate
Biochemical pregnancy n (%) 213 (70.3%)
Clinical pregnancy n (%) 179 (59.1%)
Ongoing pregnancy n (%) 153 (50.5%)a putative negative effect of the antagonist in the hormo-
nal profile to sustain implantation.
The proposed approach offers a flexible alternative so-
lution in cases when GnRH agonist for triggering final
oocyte maturation (OHSS-free clinic [13]) is not feasible,
i.e. in patients treated with a long protocol or patients
not accepting embryo transfer cancellation. Also, admin-
istration of GnRH antagonist in the luteal phase may
prove useful in patients who develop severe OHSS des-
pite the use of preventive measures.
Conclusions
In conclusion, the current study suggests, for the first
time, that successful outpatient management of severe
OHSS with antagonist treatment in the luteal phase is
feasible and is associated with rapid regression of the
syndrome, challenging the dogma of inpatient manage-
ment. The proposed management is a flexible approach
that minimizes unnecessary embryo transfer cancella-
tions in the majority of high risk for OHSS patients.
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